公开(公告)号：NZ772688A

公开(公告)日：2022-09-30

申请号：NZ77268811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Use of ibrutinib as an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), in the manufacture of a medicament for treating chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), wherein said medicament is to be administered in an oral dose of 420 mg of said inhibitor once per day until progression of the CLL or SLL or unacceptable toxicity; and lymphocytosis is not considered progression of the CLL or SLL.

公开(公告)号：AU2020202752B2

公开(公告)日：2022-04-07

申请号：AU2020202752

申请日：2020-04-24

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：NZ755485A

公开(公告)日：2021-04-30

申请号：NZ75548511

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK ,  FYFE GWEN ,  BUGGY JOSEPH

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Use of ibrutinib in the manufacture of a medicament for treating multiple myeloma (MM) in an individual in need thereof, wherein the medicament is formulated for administration at an ibrutinib dosage of about 420 to about 840 mg once per day in a solid oral dosage form. Preferably the medicament is in the form of capsules containing a once per day dosage of 420 mg, 560 mg or 840 mg.

公开(公告)号：AU2018204179A1

公开(公告)日：2018-07-05

申请号：AU2018204179

申请日：2018-06-12

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：SG10201702913XA

公开(公告)日：2017-06-29

申请号：SG10201702913X

申请日：2012-10-19

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J

Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.

公开(公告)号：NZ702485A

公开(公告)日：2016-04-29

申请号：NZ70248511

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK D ,  FYFE GWEN ,  BUGGY JOSEPH J

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Disclosed is the use of the inhibitor of Bruton’s tyrosine kinase (Btk) (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one / ibrutinib / PCI-32765 in the preparation of a medicament for treating Waldenstrom’s macroglobulinemia in an individual wherein, the medicament comprises from 420mg to 840mg of said inhibitor, the medicament is formulated for oral administration, and said individual has already received at least one prior therapy for Waldenstrom’s macroglobulinemia.

公开(公告)号：MX391121B

公开(公告)日：2025-03-19

申请号：MX2017014058

申请日：2014-04-16

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61P35/00 ,  A61K31/519 ,  A61K39/395

Abstract: La presente invención se refiere a procedimientos de tratamiento de un cáncer hematológico que comprenden administrar un agente antineoplásico a un sujeto identificado por tener una elevada movilización de una subpoblación de linfocitos de un tumor maligno tras la administración de un inhibidor de Btk irreversible. También se proporcionan procedimientos de identificación de sujetos para el tratamiento y el análisis de células movilizadas de un tumor maligno hematológico tras la administración de un inhibidor de Btk irreversible.

公开(公告)号：MX380899B

公开(公告)日：2025-03-12

申请号：MX2020004438

申请日：2012-12-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID J ,  HEDRICK ERIC ,  FYFE GWEN ,  BUGGY JOSEPH J ,  ELIAS LAURENCE ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/496 ,  A61P35/00

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：AU2022201972A1

公开(公告)日：2022-04-14

申请号：AU2022201972

申请日：2022-03-22

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：AU2022201742A1

公开(公告)日：2022-04-07

申请号：AU2022201742

申请日：2022-03-14

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.